CTKB — Cytek Biosciences, Inc.

Summary of Cytek Biosciences Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $62.1 million, an 8% increase year-over-year, marking the highest quarterly revenue in the company's history.
• Full Year 2025 Revenue: $201.5 million, a 1% increase compared to 2024.
• Gross Profit: Q4 gross profit was $32.9 million (53% margin), down from $33.7 million (59% margin) in Q4 2024. Full year gross profit was $104.5 million (52% margin), down from $111.1 million (55% margin) in 2024.
• Net Loss: Q4 net loss of $44.1 million, including a $38.1 million valuation allowance against deferred tax assets. Full year net loss was $66.5 million.
• Adjusted EBITDA: Q4 adjusted EBITDA was $4.5 million, down from $12.5 million in Q4 2024. Full year adjusted EBITDA was $5 million, down from $22.4 million in 2024.
• Cash Position: Cash and marketable securities totaled $261.5 million at year-end, down from $277.9 million in 2024.

2. Strategic Updates and Business Highlights

• Geographic Performance: Strong growth in EMEA (21%) and APAC (15%) in Q4, driven by academic and government customers. U.S. revenue grew 5%, supported by demand from academic and government sectors.
• Recurring Revenue: Represented 34% of total revenue, growing 21% year-over-year, driven by an expanding installed base of instruments.
• Product Growth: Instrument sales grew 22% in 2025, with a notable 26% growth in Q4. The new Cytek Aurora Evo system contributed significantly to this growth.
• Operational Improvements: Established a new manufacturing facility in Singapore, enhancing supply chain resilience and operational efficiency.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Projected revenue between $205 million and $212 million, assuming stable market conditions and no significant tariff changes. The guidance reflects expected continued growth in service and reagent businesses, alongside modest growth in instruments.

4. Bad News, Challenges, or Points of Concern

• Declining Metrics: Gross profit margins decreased due to higher material costs and operational expenses. Operating expenses rose significantly, leading to a loss from operations of $40.4 million for the year.
• Market Challenges: The company faced a challenging market environment in 2025, with revenue declines in the first half of the year due to public policy issues affecting life sciences spending.
• Valuation Allowance: The substantial net loss in Q4 was impacted by a one-time accounting adjustment related to deferred tax assets, raising concerns about future tax benefits realization.

5. Notable Q&A Insights

• Market Growth: Management indicated that while the flow cytometry market has been experiencing lower growth rates, they expect a rebound in 2026, particularly in APAC and academic sectors.
• Budget Trends: Q4 growth was attributed to a normalization in academic spending and catch-up disbursements from the NIH, suggesting a more stable budget environment moving forward.
• Sales Strategy: Cytek plans to continue investing in its sales force and reagent sales to drive future growth, indicating a focus on both new customer acquisition and expanding existing customer capacities.

Overall, Cytek Biosciences demonstrated resilience in a challenging market, achieving significant revenue growth in Q4 and maintaining a strong cash position, while also addressing operational challenges and strategic investments for future growth.